背景:肌肉减少症,与年龄相关的肌肉功能下降的标志,显著影响老年人身体健康。本系统综述旨在探讨肠道菌群对少肌症的影响。
方法:截至2023年9月24日的出版物在四个数据库上进行了审查-PubMed,WebofScience,科克伦图书馆,和Embase-使用相关关键字。非英语论文被忽略。收集并检查了有关肌少症患者/动物模型中肠道微生物群改变的数据。
结果:包括13项人类和8项动物研究。人体研究涉及732名肌少症或潜在的肌少症参与者(57-98岁)和2559名健康受试者(54-84岁)。动物研究包括五只小鼠和三只大鼠实验。结果表明,机会病原体如肠杆菌科细菌的增加,伴随着几种代谢物相关生物体的变化。例如,与马尿酸代谢相关的拟杆菌流量增加。然而,罗斯布里亚,粪杆菌,普氏粪杆菌,真细菌代表,Akkermansiaa,球菌,Clostridium_XIVa,Ruminocycaceae,拟杆菌,梭菌属,参与尿石素A生产的真细菌,和乳酸菌,拟杆菌,与胆汁酸代谢相关的梭状芽孢杆菌的丰度降低。
结论:年龄相关的少肌症和肠道菌群改变是错综复杂的联系。短链脂肪酸代谢,尿石素A,胆汁酸的产生可能是肠-肌轴途径中的关键因素。补充有益的代谢物相关微生物可以增强肌肉功能,减轻肌肉萎缩,并减缓肌肉减少症的进展。
BACKGROUND: Sarcopenia, a hallmark of age-related muscle function decline, significantly impacts elderly physical health. This systematic
review aimed to investigate the impact of gut microbiota on sarcopenia.
METHODS: Publications up to September 24, 2023 were scrutinized on four databases - PubMed, Web of Science, Cochrane Library, and Embase - using relevant keywords. Non-English papers were disregarded. Data regarding gut microbiota alterations in sarcopenic patients/animal models were collected and examined.
RESULTS: Thirteen human and eight animal studies were included. The human studies involved 732 sarcopenic or potentially sarcopenic participants (aged 57-98) and 2559 healthy subjects (aged 54-84). Animal studies encompassed five mouse and three rat experiments. Results indicated an increase in opportunistic pathogens like Enterobacteriaceae, accompanied by changes in several metabolite-related organisms. For example, Bacteroides fluxus related to horse uric acid metabolism exhibited increased abundance. However, Roseburia, Faecalibacterium, Faecalibacterium prausnitzii, Eubacterium retale, Akkermansiaa, Coprococcus, Clostridium_XIVa, Ruminococcaceae, Bacteroides, Clostridium, Eubacterium involved in urolithin A production, and Lactobacillus, Bacteroides, and Clostridium associated with bile acid metabolism displayed decreased abundance.
CONCLUSIONS: Age-related sarcopenia and gut microbiota alterations are intricately linked. Short-chain fatty acid metabolism, urolithin A, and bile acid production may be pivotal factors in the gut-muscle axis pathway. Supplementation with beneficial metabolite-associated microorganisms could enhance muscle function, mitigate muscle atrophy, and decelerate sarcopenia progression.